In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...
This article is based on a poster originally authored by Peter Hsueh, Lili Qin, Jane Liu and Wenlin Ren. Target proteins are central to the antibody discovery process. These reagents play a critical ...
Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.
News-Medical.Net on MSN
Artificial intelligence unlocks new frontiers in RNA drug design
In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
Vietnam Investment Review on MSN
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, science-forward drug development. By reducing reliance on animal models and ...
Vin Singh Founder and Chief Executive Officer BullFrog AI Holdings, Inc.
Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback